ストックスクリーナーアプリを入手
0.5029
0.90%
0.0045
アフターアワーズ：
.49
-0.0129
-2.57%
前日終値:
$0.4984
開ける：
$0.5
24時間の取引高:
205.71K
Relative Volume:
1.28
時価総額：
$19.53M
収益：
$7.88M
当期純損益:
$-69.20M
株価収益率:
-0.2748
EPS:
-1.83
ネットキャッシュフロー:
$-69.73M
1週間 パフォーマンス:
-3.57%
1か月 パフォーマンス:
-11.77%
6か月 パフォーマンス:
-31.12%
1年 パフォーマンス:
-53.00%
1日の値動き範囲:
$0.486
$0.5195
1週間の範囲:
$0.486
$0.546
52週間の値動き範囲:
$0.475
$1.56
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
名前
Bolt Biotherapeutics Inc
セクター
電話
650-665-9295
住所
900 CHESAPEAKE DRIVE, REDWOOD CITY
BOLT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
0.5029 | 19.53M | 7.88M | -69.20M | -69.73M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | 開始されました | Guggenheim | Buy |
| 2021-03-02 | 開始されました | Morgan Stanley | Overweight |
| 2021-03-02 | 開始されました | SVB Leerink | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
Bolt Biotherapeutics Inc (BOLT) 最新ニュース
BOLT Stock Earnings: Bolt Biotherapeutics Misses EPS, Beats Revenue for Q2 2024 - MSN
Bolt Biotherapeutics shifts to Nasdaq Capital Market By Investing.com - Investing.com Nigeria
Bolt Biotherapeutics shifts to Nasdaq Capital Market - Investing.com India
Bolt Biotherapeutics, Inc. Announces Board and Committee Changes, Effective December 31, 2024 - Marketscreener.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Shares Purchased by Fmr LLC - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Bolt Biotherapeutics stock hits 52-week low at $0.53 By Investing.com - Investing.com Australia
Bolt Biotherapeutics stock hits 52-week low at $0.53 - Investing.com India
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesBOLT - The Eastern Progress Online
BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully - Simply Wall St
Bolt Biotherapeutics (BOLT) Stock Surges Amid Biotech Sector Mov - GuruFocus.com
Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B - Endpoints News
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Bolt Biotherapeutics stock hits 52-week low at $0.54 By Investing.com - Investing.com Canada
Bolt Biotherapeutics stock hits 52-week low at $0.54 - Investing.com
HC Wainwright Issues Pessimistic Forecast for BOLT Earnings - Defense World
Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look - TipRanks
Bolt Biotherapeutics Reports Q3 2024 Financial Results - TipRanks
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot - Houston Chronicle
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation - Yahoo Finance
BOLTBolt Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting - The Manila Times
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Marketscreener.com
Bolt Biotherapeutics (STU:6LP) Cash Flow from Investing : €52.47 Mil (TTM As of Jun. 2024) - GuruFocus.com
Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
BOLT Stock Surges Over 5% Amidst Biotech Sector's Mixed Performa - GuruFocus.com
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - News & Insights
Bolt Biotherapeutics (BOLT) Stock Surges Amid Broad Biotech Indu - GuruFocus.com
Renaissance Technologies LLC Sells 240,898 Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) - Defense World
Renaissance Technologies LLC Has $208,000 Stock Holdings in Hesai Group (NASDAQ:HSAI) - Defense World
Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Drops By 39.1% - Defense World
Bolt Biotherapeutics Inc (BOLT) 財務データ
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):